1. Home
  2. IKNA vs BRID Comparison

IKNA vs BRID Comparison

Compare IKNA & BRID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKNA
  • BRID
  • Stock Information
  • Founded
  • IKNA 2016
  • BRID 1932
  • Country
  • IKNA United States
  • BRID United States
  • Employees
  • IKNA N/A
  • BRID N/A
  • Industry
  • IKNA Biotechnology: Pharmaceutical Preparations
  • BRID Specialty Foods
  • Sector
  • IKNA Health Care
  • BRID Consumer Staples
  • Exchange
  • IKNA Nasdaq
  • BRID Nasdaq
  • Market Cap
  • IKNA 61.8M
  • BRID 72.6M
  • IPO Year
  • IKNA 2021
  • BRID N/A
  • Fundamental
  • Price
  • IKNA $1.13
  • BRID $7.79
  • Analyst Decision
  • IKNA Buy
  • BRID
  • Analyst Count
  • IKNA 2
  • BRID 0
  • Target Price
  • IKNA $3.00
  • BRID N/A
  • AVG Volume (30 Days)
  • IKNA 96.4K
  • BRID 3.0K
  • Earning Date
  • IKNA 05-08-2025
  • BRID 05-30-2025
  • Dividend Yield
  • IKNA N/A
  • BRID N/A
  • EPS Growth
  • IKNA N/A
  • BRID N/A
  • EPS
  • IKNA N/A
  • BRID N/A
  • Revenue
  • IKNA N/A
  • BRID $221,348,000.00
  • Revenue This Year
  • IKNA N/A
  • BRID N/A
  • Revenue Next Year
  • IKNA N/A
  • BRID N/A
  • P/E Ratio
  • IKNA N/A
  • BRID N/A
  • Revenue Growth
  • IKNA N/A
  • BRID N/A
  • 52 Week Low
  • IKNA $0.97
  • BRID $7.52
  • 52 Week High
  • IKNA $1.94
  • BRID $14.69
  • Technical
  • Relative Strength Index (RSI)
  • IKNA 43.57
  • BRID 37.52
  • Support Level
  • IKNA $1.22
  • BRID $7.82
  • Resistance Level
  • IKNA $1.29
  • BRID $8.37
  • Average True Range (ATR)
  • IKNA 0.09
  • BRID 0.22
  • MACD
  • IKNA -0.01
  • BRID 0.04
  • Stochastic Oscillator
  • IKNA 23.33
  • BRID 19.10

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

Share on Social Networks: